Novo Nordisk Shares Sink 21% as Obesity Shot Trails Lilly Rival

CagriSema posts 20.2% weight loss versus 23.6% for tirzepatide, prompting multiple downgrades and intensifying scrutiny ahead of 2032 patent cliffs.